# Hour 02: 02:00-02:59 - Overnight Trough and First IND Dose

Released on 1 May 2026 | CEO Kevin Kawchak | ChemicalQDevice

## Hour Summary

Hour 02 sees the overnight low-activity trough end with the first investigational
agent (TRAVERSE protocol BTK-d / placebo) administration of the continuous
trial cycle at SITE-B. Total network workload is low (3 active sessions),
but the IND dosing event triggers the highest-priority RTCT signal of the
shift.

## Cross-Site Status at 02:00 UTC

| Site | Patients On-Site | Active Procedures | Robots Standby | Robots Active | Signal Link |
|------|------------------|-------------------|----------------|---------------|-------------|
| SITE-A | 5 | 0 | 29 | 0 | UP (140 ms) |
| SITE-B | 5 | 0 | 29 | 0 | UP (162 ms) |
| SITE-C | 3 | 0 | 29 | 0 | UP (199 ms) |
| SITE-D | 3 | 0 | 29 | 0 | UP (121 ms) |

## New Patient Arrivals

| Patient ID | Site | Time | Age | Sex | Cancer Type | Stage | ECOG | Robot |
|------------|------|------|-----|-----|-------------|-------|------|-------|
| PAT-CONT-0007 | SITE-B | 02:18 | 67 | M | Mantle cell lymphoma (TRAVERSE) | II | 1 | Humanoid + IND administration |
| PAT-CONT-0008 | SITE-A | 02:47 | 73 | F | HCC | III | 2 | Steerable Needle (9) |

## Minute-Resolution Activity Log

```
02:00  Hour-boundary FDA reconciliation: 3/3 endpoints accepted.
02:01-02:17 Network quiet. Continuous telemetry only.
02:18  PAT-CONT-0007 check-in at SITE-B. TRAVERSE Cycle 1 Day 1 dosing visit.
02:19  HUMAN-01 (SITE-B) wakes. Pharmacy retrieves IND blinded kit BTK-d-0042.
02:20  IRT (interactive response tech) confirms randomization arm: ARM-A.
02:21  Pre-dose vitals: BP 144/82, HR 88, SpO2 96%.
02:22  PAT-CONT-0007 escorted by HUMAN-01 to infusion bay 2.
02:23  Pre-dose ECG captured by IMAGE-04 (SITE-B). QTc 412 ms.
02:24  Drug accountability check: HUMAN-01 + SSO + pharmacist trio sign.
02:25  IND infusion start. Rate 60 mg/hr per protocol.
02:26-02:54  Infusion ongoing. Vitals q5min. No reactions.
02:55  Infusion complete. Total dose 60 mg administered.
02:56  Post-dose vitals: BP 138/80, HR 82, SpO2 97%. QTc 414 ms (no change).
02:57  IND endpoint streamed: TRAVERSE-CONT-0007-IND-C1D1.
02:58  FDA ack 02:57+9s.
02:47  (parallel) PAT-CONT-0008 check-in SITE-A. Liver ablation pre-procedure.
02:48-02:55 STEER-01 wakes. CT registration. Pre-procedure safety matrix.
02:56-02:58 Steerable needle insertion to HCC lesion (1 of 2). Position OK.
02:59  Hour 02 close. PSL re-snapshot. C-PSL window now spans 3 hours.
```

## Departures This Hour

None.

## Adverse Events

None this hour. Post-IND vitals stable; QTc unchanged.

## Investigational Drug Administrations

- PAT-CONT-0007 (SITE-B): IND blinded kit BTK-d-0042, ARM-A, 60 mg infusion
  over 30 min. Drug accountability log entry IDA-0042-001.

## Cross-Site Utilization

- SITE-A: 13 robot-active minutes (STEER-01)
- SITE-B: 41 robot-active minutes (HUMAN-01 + IMAGE-04 ECG)
- SITE-C: 0
- SITE-D: 0
- Network utilization: 0.78%

## Regulatory Compliance Notes

### ICH E6(R3) - Adaption
- IRT-blinded randomization confirmed under section 4.6.

### 21 CFR Part 50 - Adaption
- TRAVERSE Cycle 1 Day 1 informed consent re-affirmed verbally and digitally.

### 21 CFR Part 312 - Adaption
- Drug accountability under section 312.62 fully documented.
- IND safety reporting clock starts at 02:25 (T0 dose start).

## RTCT Signal Stream Summary

| Signal ID | Patient | Endpoint | Latency to FDA |
|-----------|---------|----------|----------------|
| TRAVERSE-CONT-0007-IND-C1D1 | PAT-CONT-0007 | IND C1D1 dose complete | 9 s |
| TRAVERSE-CONT-0008-ABL01-START | PAT-CONT-0008 | Ablation needle 1 placed | (in progress at 02:59) |
